Alnylam Pharmaceuticals, Inc. Detailed Financials
Full historical quarterly statements
| Metric | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1.17B | 1.10B | 1.25B | 773.7M | 594.2M | 593.2M | 500.9M | 659.8M |
| Cost of Goods Sold | 211.1M | 267.7M | 197.2M | 143.0M | 71.0M | 102.8M | 85.9M | 68.7M |
| Gross Profit | 956.1M | 829.3M | 1.05B | 630.7M | 523.1M | 490.3M | 415.0M | 591.2M |
| R&D Expenses | 364.9M | 372.2M | 358.8M | 323.6M | 265.1M | 300.2M | 270.9M | 294.1M |
| Operating Expenses | 687.4M | 697.6M | 683.8M | 646.9M | 505.1M | 595.5M | 491.9M | 542.5M |
| Operating Income | 268.6M | 131.7M | 368.0M | -16.2M | 18.1M | -105.2M | -76.9M | 48.6M |
| Other Income / Gains | -47.0M | 29.4M | -129.0M | -19.2M | -59.7M | -88.8M | -31.8M | -59.8M |
| Net Income | 206.0M | 186.4M | 251.1M | -66.3M | -57.5M | -83.8M | -111.6M | -16.9M |
| EPS (Diluted) | 1.55 | 1.41 | 1.91 | -0.51 | -0.44 | -0.65 | -0.87 | -0.13 |
| Reported Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Gross Profit Ratio | 0.819 | 0.756 | 0.842 | 0.815 | 0.88 | 0.827 | 0.829 | 0.896 |
| General And Administrative Expenses | 322.6M | 325.4M | 322.1M | 323.3M | 239.9M | 295.3M | 221.0M | 248.4M |
| Selling And Marketing Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling General And Administrative Expenses | 322.6M | 325.4M | 322.1M | 323.3M | 239.9M | 295.3M | 221.0M | 248.4M |
| Other Expenses | 0 | 0 | 2.9M | 0 | 0 | 0 | 0 | 0 |
| Cost And Expenses | 898.5M | 965.3M | 881.0M | 789.9M | 576.1M | 698.3M | 577.8M | 611.2M |
| Interest Income | 26.6M | 26.6M | 28.7M | 27.5M | 28.7M | 31.0M | 32.1M | 29.2M |
| Interest Expense | 69.3M | 129.3M | 44.4M | 40.2M | 38.6M | 39.0M | 34.4M | 33.3M |
| Depreciation And Amortization | 13.6M | 13.5M | 13.8M | 13.9M | 14.4M | 14.2M | 14.0M | 15.0M |
| Ebitda | 304.5M | 304.0M | 297.2M | 18.8M | 11.5M | -140.9M | -60.3M | 37.1M |
| Ebitdaratio | 0.261 | 0.277 | 0.238 | 0.024 | 0.019 | -0.238 | -0.12 | 0.056 |
| Operating Income Ratio | 0.23 | 0.12 | 0.295 | -0.021 | 0.03 | -0.177 | -0.154 | 0.074 |
| Income Before Tax | 221.7M | 161.1M | 239.0M | -35.4M | -41.6M | -194.0M | -108.7M | -11.2M |
| Income Before Tax Ratio | 0.19 | 0.147 | 0.191 | -0.046 | -0.07 | -0.327 | -0.217 | -0.017 |
| Income Tax Expense | -15.7M | -25.3M | -12.1M | 30.9M | 15.9M | -110.2M | 2.9M | 5.7M |
| Net Income Ratio | 0.176 | 0.17 | 0.201 | -0.086 | -0.097 | -0.141 | -0.223 | -0.026 |
| Epsdiluted | 1.51 | 1.37 | 1.84 | -0.51 | -0.44 | -0.65 | -0.87 | -0.13 |
| Weighted Average Shs Out | 132.9M | 132.2M | 131.4M | 129.7M | 129.7M | 128.6M | 128.6M | 126.7M |
| Weighted Average Shs Out Dil | 138.2M | 136.3M | 137.3M | 129.7M | 129.7M | 128.6M | 128.6M | 126.7M |